Fig. 5

Anti-leukemic effects of sesamolin at different time points. Normal and leukemic mice were classified according to the criteria listed in Table 2, and administered with sesamolin as enumerated in Table 3. A Mouse blood and bone marrow cells visualized with Wright Giemsa staining. Arrows () indicate banded neutrophils and arrows (➔) indicate myeloblasts. Data are representative of experiments repeated at least three times. B Ratios (%) of banded neutrophils in blood leukocytes and myeloblasts in bone marrow cells. Data are representative of experiments repeated at least three times with triplicate samples and are shown as mean ± SD. **P < 0.01, *P < 0.05 vs. group 3 (one-way ANOVA with Dunnett’s post-hoc tests). Group 1, normal BALB/c mice; group 2, Normal BALB/c mouse administered with 10 mg/kg sesamolin (in CMC) from day 5; group 3, WEHI-3B-injected BALB/c mice; group 4, WEHI-3B-injected BALB/c mouse and administered with 10 mg/kg sesamolin in CMC from day 0; group 5, WEHI-3B-injected BALB/c mouse administered with 10 mg/kg sesamolin in CMC from day 5